FDA Expands Recall Of Blood Pressure Drugs Again

(CNN) — Torrent Pharmaceuticals Ltd. has expanded its voluntary recall of two blood pressure medications after trace amounts of a potentially cancer-causing impurity were found during testing. The recall affects Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets. Tests of some of those medications revealed amounts of N-methylnitrosobutyric acid (NMBA) that were above the US Food and Drug Administration’s daily acceptable levels. This recall is related to the valsartan recall that has been expanded multiple times since July, when separate lots of blood pressure medications from different companies began being pulled from pharmacy shelves. The medications all contained either valsartan, losartan or irbesartan and had traces of these impurities that pose a cancer risk to users. The FDA has begun testing all heart drugs called angiotensin II receptor blockers for these impurities. Also known as ARBs, they block a potent chemical in the blood called angiotensin that causes muscles surrounding blood vessels to contract. When the chemical binds, it narrows the vessels, and that can cause high blood pressure. What this recall includes This current expansion includes three additional lots of Losartan Potassium Tablets USP and two lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP. Patients currently taking the medication should continue doing so “as the risk of harm to the patient’s health may be higher if the treatment i...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Syndicated CBSN Boston CNN Recall Valsartan Source Type: news

Related Links:

Since the beginning of COVID-19 pandemics, it is known that the severe course of the disease occurs mostly among elderly, whereas it is rare among children and young adults. Comorbidities, in particular diabetes and hypertension, clearly associated with age, besides obesity and smoke are strongly associated with the need of intensive treatment and a dismal outcome. A weaker immunity of the elderly has been proposed as a possible explanation of this uneven age distribution. Along the same line, anecdotal information from Wuhan, China mentioned a severe course of COVID-19 in a child treated for leukemia.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Conditions:   Non-melanoma Skin Cancer;   Melanoma;   Hypertension Interventions:   Drug: Hydrochlorothiazide;   Drug: Angiotensin-converting enzyme (ACE) inhibitors Sponsors:   Canadian Network for Observational Drug Effect Studies, CNODES;   Drug Safety and Effectiveness Network, Canada;   Canadian Institutes of Health Research (CIHR) Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A friend of mine takes a statin medication each day to lower his cholesterol. More than once I’ve heard him say “I ate too much! I’m going to have to take an extra pill.” Never mind that it doesn’t work that way — a single additional statin pill won’t make much difference to his cholesterol or his health. And never mind that you shouldn’t self-adjust the dose of your medications (talk to your doctor before making any changes in medication dosing). But my friend’s overindulging does bring up the question of whether starting medications for conditions like high blood pres...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Exercise and Fitness Health Healthy Eating Heart Health Hypertension and Stroke Source Type: blogs
After the outbreak of the coronavirus 2019-nCov (COVID-19) in Wuhan, China, in December 2019,[1] the disease rapidly became a global pandemic. Infection rates peaked and began to decline in some Asian countries by March 2020, but Europe and the US are now among the most affected regions.[2] Most COVID-19 infections are characterized by only mild symptoms of fever and cough; however, there is a high risk of severe pulmonary infection and death, in particular for the elderly and populations with comorbidities such as diabetes, hypertension and cardiopulmonary diseases.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Source Type: research
ConclusionsTumor responses and PFS in our study were in line with other real-life clinical data and they seem to be inferior to the reported in the SELECT trial, probably related to the higher number of patients with prior MKI therapy, comorbidities, and poor performance status. Although virtually all patients experienced AEs, most of them were manageable and rarely a definitive withdrawal was necessary.
Source: Endocrine - Category: Endocrinology Source Type: research
CONCLUSIONS: Apatinib was safe and effective in the management of patients with ES-SCLC and can be considered as a treatment option after failure of at least two prior chemotherapy regimens. ClinicalTrials.gov identifier. NCT02995187 IMPLICATIONS FOR PRACTICE: This study indicated the acceptable toxicity profile and promising efficacy of apatinib in the management of patients with extensive-stage small cell lung cancer after failure from at least two prior chemotherapy regimens. Secondary hypertension can be a potential prognostic factor for apatinib treatment. PMID: 32250517 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
This study delves into the mechanisms by which a short period of fasting can accelerate wound healing. Fasting triggers many of the same cellular stress responses, such as upregulated autophagy, as occur during the practice of calorie restriction. It isn't exactly the same, however, so it is always worth asking whether any specific biochemistry observed in either case does in fact occur in both situations. In particular, the period of refeeding following fasting appears to have beneficial effects that are distinct from those that occur while food is restricted. Multiple forms of therapeutic fasting have been repor...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Bottino LG, Fuchs FD Abstract Introduction: Angiotensin receptor blockers (ARBs) are recommended as preferential drugs in the treatment of hypertension by guidelines. In this review, we reappraise their effectiveness to preventing major cardiovascular outcomes and the recent concerns with new adverse effects.Areas covered: ARBs were not superior to placebo in the prevention of all-cause deaths and combined cardiovascular events in seven randomized controlled trials (RCT). Several meta-analyses, with large number of participants, confirmed these findings. Three RCT trials, published in top journals, were re...
Source: Expert Review of Cardiovascular Therapy - Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research
In conclusion, protection of the thiol disulfide homeostasis is of great importance for the human being. Evidence achieved so far has proposed that thiol-disulfide homeostasis is an important issue needs to elucidate wholly. PMID: 32233181 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Update: On April 1, 2020, the FDA requested manufacturers to withdraw all prescription and over-the-counter (OTC) ranitidine drugs (Zantac, others) from the market immediately, due to the presence of a contaminant known as N-Nitrosodimethylamine (NDMA). Although the FDA did not observe unacceptable levels of NDMA in many of the samples they tested, they have determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures. As a result of this recall, ranitidine products will no longer be available for prescription or OTC use in the US. The FDA is also advising co...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Digestive Disorders Drugs and Supplements Source Type: blogs
More News: Avalide | Avapro | Cancer | Cancer & Oncology | Cardiology | Chemistry | Contracts | Cozaar | Diovan | Food and Drug Administration (FDA) | Health | Heart | Hydrochlorothiazide | Hypertension | Losartan | Potassium | Sports Medicine